Skip to content

The effect of injectable and sustained-release pharmaceutical form of celecoxib in the treatment of knee osteoarthritis patients

Clinical trial of hybrid thermosensitive hydrogel based on hyaluronic acid containing celecoxib for knee osteoarthritis patients

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20221101056363N1
Enrollment
84
Registered
2022-11-22
Start date
2023-01-21
Completion date
Unknown
Last updated
2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis. Osteoarthritis of knee

Interventions

Intervention 1: Intervention group: Patients with primary OA of the knee, who after checking the entry and exit criteria and signing the consent form, were randomly injected with temperature-dependent

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 80 Years

Inclusion criteria

Inclusion criteria: Primary one-sided osteoarthritis of the knee that has been at least 6 months since it became symptomatic (painful) and aggravated by weight bearing and has not responded properly to conservative treatment. Radiographic arthrosis stage 1, 2 and 3 of Kellgren Lawrence classification (KLS) Signing the consent form and complete and voluntary willingness to participate in the study

Exclusion criteria

Exclusion criteria: Any history of trauma (fracture), surgery and tumor in the knee and lower limb of the same side Clinically obvious alignment disorder Any history of invasive procedure, injection or infection in the desired knee during the last 6 months Any blood disorder History or history of autoimmune disease or being treated with immunosuppressors and non-removable corticosteroids Patients with secondary osteoarthritis Proven liver and kidney disorders Irrevocable consumption of oral or topical painkillers Cognitive impairments and the inability to walk without a walker or the help of others CVA and similar problemsInsulin-dependent diabetic patients Patients with spine disorders and radicular pain to the lower limbs

Design outcomes

Primary

MeasureTime frame
Evaluation of the parameters related to the immune system including the level of IL-10, TNF-a, IL-6, TGF-beta1). Timepoint: It will be performed at the beginning, second week and fourth weeks. Method of measurement: Commercial lab kits.;Liver tests including the serum level of ALT and AST. Timepoint: It will be performed at the beginning, second week and fourth weeks. Method of measurement: Commercial kits.;BUN and creatinine. Timepoint: It will be performed at the beginning, second week and fourth weeks. Method of measurement: Commercial kits.;Range of motion of the joint (goniometer and degree). Timepoint: It will be performed at the beginning, second week and fourth weeks. Method of measurement: goniometer and degree.;The sitting and standing test (number). Timepoint: It will be performed at the beginning, second week and fourth weeks. Method of measurement: Physical examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMona Alibolandi

Mashhad University of Medical Sciences

alibolandim@mums.ac.ir009851 3801205

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026